The Role of Circulating Tumor Dna (Ctdna) in Liquid Biopsy for Early Cancer Detection and Recurrence Prediction
Downloads
Traditional tissue biopsies are invasive, limited by spatial heterogeneity, and difficult to perform serially. Liquid biopsy, specifically the analysis of circulating tumor DNA (ctDNA), offers a non-invasive alternative for real-time monitoring of tumor dynamics. Objectives: This study evaluates the clinical utility of ctDNA in early-stage cancer diagnosis and the prediction of minimal residual disease (MRD) and tumor recurrence. Methods: We conducted a systematic review and meta-analysis of clinical cohorts spanning early-to-late stage solid tumors (colorectal, lung, and breast cancers) utilizing next-generation sequencing (NGS) and digital droplet PCR (ddPCR). Results: ctDNA assays demonstrated a pooled sensitivity of 76.4% for early-stage screening, which significantly increased when paired with multi-cancer early detection (MCED) protein markers. For recurrence tracking, ctDNA positivity post-surgery predicted disease relapse up to 8.2 months ahead of conventional radiological imaging (HR = 4.35, p < 0.001). Conclusion: ctDNA serves as a highly specific biomarker for early detection and a powerful tool for monitoring postoperative molecular recurrence, paving the way for personalized oncology.
[1] H. Sung et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021.
[2] R. L. Siegel, K. D. Miller, N. S. Wagle, and A. Jemal, “Cancer statistics, 2023,” CA Cancer J. Clin., vol. 73, no. 1, pp. 17–48, Jan. 2023.
[3] M. Gerlinger et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” N. Engl. J. Med., vol. 366, no. 10, pp. 883–892, Mar. 2012.
[4] D. Sulaymonov and I. Sodiqov, “Comparative evaluation of the diagnostic accuracy of CT and MRI in the detection of liver metastases,” South Aral Region Med. J., vol. 2, no. Maxsus son-2, pp. 514–520, 2026.
[5] E. Crowley, F. Di Nicolantonio, F. Loupakis, and A. Bardelli, “Liquid biopsy: Monitoring cancer-genetics in the blood,” Nat. Rev. Clin. Oncol., vol. 10, no. 8, pp. 472–484, Aug. 2013.
[6] J. C. M. Wan et al., “Liquid biopsies come of age: Towards implementation of circulating tumour DNA,” Nat. Rev. Cancer, vol. 17, no. 4, pp. 223–238, Apr. 2017.
[7] E. Heitzer, I. S. Haque, C. E. S. Roberts, and M. R. Speicher, “Current and future perspectives of liquid biopsies in genomics-driven oncology,” Nat. Rev. Genet., vol. 20, no. 2, pp. 71–88, Feb. 2019.
[8] M. Jahr et al., “DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells,” Cancer Res., vol. 61, no. 4, pp. 1659–1665, Feb. 2001.
[9] F. Diehl et al., “Circulating mutant DNA to assess tumor dynamics,” Nat. Med., vol. 14, no. 9, pp. 985–990, Sep. 2008.
[10] C. Bettegowda et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” Sci. Transl. Med., vol. 6, no. 224, Art. no. 224ra24, Feb. 2014.
[11] F. Mouliere et al., “Enhanced detection of circulating tumor DNA by fragment size analysis,” Sci. Transl. Med., vol. 10, no. 466, Art. no. eaat4921, Nov. 2018.
[12] A. M. Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage,” Nat. Med., vol. 20, no. 5, pp. 548–554, May 2014.
[13] T. Reinert et al., “Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer,” JAMA Oncol., vol. 5, no. 8, pp. 1124–1131, Aug. 2019.
[14] J. D. Cohen et al., “Detection and localization of surgically resectable cancers with a multi-analyte blood test,” Science, vol. 359, no. 6378, pp. 926–930, Feb. 2018.
[15] M. C. Liu et al., “Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA,” Ann. Oncol., vol. 31, no. 6, pp. 745–759, Jun. 2020.
[16] S. Cristiano et al., “Genome-wide cell-free DNA fragmentation in patients with cancer,” Nature, vol. 570, no. 7761, pp. 385–389, Jun. 2019.
[17] J. Tie et al., “Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer,” Sci. Transl. Med., vol. 8, no. 346, Art. no. 346ra92, Jul. 2016.
[18] I. Garcia-Murillas et al., “Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer,” Sci. Transl. Med., vol. 7, no. 302, Art. no. 302ra133, Aug. 2015.
[19] C. Abbosh et al., “Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution,” Nature, vol. 545, no. 7655, pp. 446–451, May 2017.
[20] A. A. Chaudhuri et al., “Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling,” Cancer Discov., vol. 7, no. 12, pp. 1394–1403, Dec. 2017.
[21] K. Pantel and C. Alix-Panabières, “Liquid biopsy and minimal residual disease—Latest advances and implications for cure,” Nat. Rev. Clin. Oncol., vol. 16, no. 7, pp. 409–424, Jul. 2019.
[22] A. Dasari et al., “ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal–Anal Task Forces whitepaper,” Nat. Rev. Clin. Oncol., vol. 17, no. 12, pp. 757–770, Dec. 2020.
[23] M. Ignatiadis, G. W. Sledge, and S. S. Jeffrey, “Liquid biopsy enters the clinic—Implementation issues and future challenges,” Nat. Rev. Clin. Oncol., vol. 18, no. 5, pp. 297–312, May 2021.
Copyright (c) 2026 American Journal of Biomedicine and Pharmacy

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

